Monthly Archives: January 2018
P145 GOLIMUMAB DRUG LEVELS DURING MAINTENANCE THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS
Therapeutic drug monitoring (TDM) has emerged as a means to optimize biologics and guide clinical decisions in inflammatory bowel disease (IBD). Golimumab (GOL) is a human monoclonal antibody to TNF-alpha approved for treatment of moderate-to-severe ul… Continue reading
Posted in News
Comments Off on P145 GOLIMUMAB DRUG LEVELS DURING MAINTENANCE THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS
P147 IMPLEMENTATION OF A NEW ORAL CONTRAST AGENT FOR CT AND MR ENTEROGRAPHY IN PEDIATRIC IBD CLINICAL PRACTICE: IMPACT ON TOLERABILITY, DISTENSION, IMAGE QUALITY AND DIAGNOSTIC CONFIDENCE
To evaluate the ability of pediatric patients with suspected IBD to ingest a new oral contrast agent at CT or MR enterography (CTE/MRE) and to determine the impact on small bowel (SB) distension and diagnostic confidence. Continue reading
Posted in News
Comments Off on P147 IMPLEMENTATION OF A NEW ORAL CONTRAST AGENT FOR CT AND MR ENTEROGRAPHY IN PEDIATRIC IBD CLINICAL PRACTICE: IMPACT ON TOLERABILITY, DISTENSION, IMAGE QUALITY AND DIAGNOSTIC CONFIDENCE
1 EFFECTIVENESS OF ORAL IRON SUPPLEMENTATION IN THE TREATMENT OF ANEMIA ASSOCIATED WITH PEDIATRIC ULCERATIVE COLITIS FLARE
Iron deficiency anemia (IDA) is the most prevalent extra-intestinal sequelae of pediatric inflammatory bowel disease. As IV iron therapy options expand, use of oral iron supplementation (oral Fe) to treat IDA in the presence of increased ulcerative col… Continue reading
Posted in News
Comments Off on 1 EFFECTIVENESS OF ORAL IRON SUPPLEMENTATION IN THE TREATMENT OF ANEMIA ASSOCIATED WITH PEDIATRIC ULCERATIVE COLITIS FLARE
P150 MICROBIOME RISK SCORE (MRS) IN THE DIAGNOSIS AND CLASSIFICATION OF INFLAMMATORY BOWEL DISEASE
Inflammatory bowel disease (IBD) is a common, complex and chronic condition of the GI tract. Crohn’s disease (CD) and ulcerative colitis (UC) are the two main forms of IBD. Dysregulated immune response due to alterations in microbial composition in g… Continue reading
Posted in News
Comments Off on P150 MICROBIOME RISK SCORE (MRS) IN THE DIAGNOSIS AND CLASSIFICATION OF INFLAMMATORY BOWEL DISEASE
P152 PATIENT EXPERIENCES WITH COLORECTAL CANCER SURVEILLANCE (CRC) IN INFLAMMATORY BOWEL DISEASE (IBD): A QUALITATIVE STUDY
Understanding how IBD patients’ experiences with colonoscopy influence their acceptance and participation in CRC surveillance colonoscopy may facilitate design and implementation of CRC surveillance strategies. The aim of this study was to define IBD… Continue reading
Posted in News
Comments Off on P152 PATIENT EXPERIENCES WITH COLORECTAL CANCER SURVEILLANCE (CRC) IN INFLAMMATORY BOWEL DISEASE (IBD): A QUALITATIVE STUDY
P149 LONG-TERM SAFETY AND EFFICACY OF FECAL MICROBIOTA TRANSPLANTATION IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH AND WITHOUT INFLAMMATORY BOWEL DISEASE: A TERTIARY CARE CENTER’S EXPERIENCE
Fecal Microbiota Transplantation (FMT) is an effective and safe therapy for antibiotic-resistant Clostridium Difficile Infection (CDI). However, FMT long-term outcomes are unknown. Therefore, in this study, we evaluated long-term FMT outcomes especiall… Continue reading
Posted in News
Comments Off on P149 LONG-TERM SAFETY AND EFFICACY OF FECAL MICROBIOTA TRANSPLANTATION IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH AND WITHOUT INFLAMMATORY BOWEL DISEASE: A TERTIARY CARE CENTER’S EXPERIENCE
P153 PATIENT, PARENT, AND PROVIDER PERCEPTIONS OF BARRIERS TO PEDIATRIC INFLAMMATORY BOWEL DISEASE CARE
Children with inflammatory bowel disease (IBD) have a significant life-long burden as a result of disease, impacted by environmental and individual barriers. Successful health system interventions require a comprehensive approach, informed by various s… Continue reading
Posted in News
Comments Off on P153 PATIENT, PARENT, AND PROVIDER PERCEPTIONS OF BARRIERS TO PEDIATRIC INFLAMMATORY BOWEL DISEASE CARE
P151 NONIMMUNITY AGAINST HEPATITIS B VIRUS IN PATIENTS WITH NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE
Currently, there are no data on the prevalence rate of hepatitis B virus (HBV) serologic markers in patients with newly diagnosed inflammatory bowel disease (IBD) in Korea, which is a hepatitis B endemic area. Continue reading
Posted in News
Comments Off on P151 NONIMMUNITY AGAINST HEPATITIS B VIRUS IN PATIENTS WITH NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE
P148 LACK OF INFLUENCE OF ELDERLY AGE AND GENDER ON THE SAFETY PROFILE OF BUDESONIDE EXTENDED-RELEASE TABLETS FOR ULCERATIVE COLITIS: A POOLED ANALYSIS OF TWO RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIALS
Budesonide extended-release tablets (multimatrix [MMX]) are indicated for induction of remission of mild to moderate ulcerative colitis (UC). Budesonide MMX is a second-generation corticosteroid with low systemic bioavailability related to extensive fi… Continue reading
Posted in News
Comments Off on P148 LACK OF INFLUENCE OF ELDERLY AGE AND GENDER ON THE SAFETY PROFILE OF BUDESONIDE EXTENDED-RELEASE TABLETS FOR ULCERATIVE COLITIS: A POOLED ANALYSIS OF TWO RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIALS
P155 REAL-WORLD SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A META-ANALYSIS
Vedolizumab (VDZ) is used to treat Crohn’s disease (CD) and ulcerative colitis (UC). Data from large real-world (RW) cohorts can further characterize safety events not fully elucidated in clinical trials. Continue reading
Posted in News
Comments Off on P155 REAL-WORLD SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A META-ANALYSIS